Monographs: Dosage forms: Specific monographs: Carbamazepine tablets (Carbamazepini compressi)

Category. Antiepileptic.

Storage. Carbamazepine tablets should be kept in a tightly closed container.

Additional information. Strength in the current WHO Model List of Essential Medicines (EML): 100 mg, 200 mg. Strength in the current WHO EML for children: 100 mg, 200 mg.

Requirements

Comply with the monograph for Tablets.

Definition. Carbamazepine tablets contain not less than 90.0% and not more than 110.0% of the amount of carbamazepine (C15H12N2O) stated on the label.

Manufacture. The formulation, manufacturing process and product packaging of Carbamazepine tablets are designed and controlled so as to ensure that, at any stage of the life cycle of the product, when tested by a suitable method such as X-ray powder diffractometry, the carbamazepine in the tablets is predominantly in the form of anhydrous polymorph form III.

Identity tests

  • Either test A alone or any two of tests B, C and D may be applied

Transfer a quantity of the powdered tablets equivalent to about 0.25 g of carbamazepine to a 50 mL beaker, add 15 mL of acetone R and boil the solution. Filter while hot, evaporate the filtrate to dryness on a water-bath and dry at 80 °C for 30 minutes. Dissolve in acetone R, allow to recrystallize and use the crystals for the following tests.

A. Carry out the examination with the crystals as described under 1.7 Spectrophotometry in the infrared region. The infrared absorption spectrum is concordant with the spectrum obtained from carbamazepine RS or with the reference spectrum of carbamazepine.

B. Carry out the test as described under 1.14.1 Chromatography, Thin-layer chromatography using silica gel R6 as the coating substance and a mixture of 78 volumes of toluene R and 22 volumes of methanol R as the mobile phase. Apply separately to the plate 2 μL of each of the following three solutions, prepared using as a solvent a mixture of equal volumes of ethanol (~750 g/L) TS and dichloromethane R. For solution (A) use 5 mg of the crystals per mL. For solution (B) use 5 mg of carbamazepine RS per mL. For solution (C) use 5 mg of carbamazepine RS and 5 mg of diazepam R per mL. After removing the plate from the chromatographic chamber allow it to dry in air and examine the chromatogram in ultraviolet light (254 nm).

The principal spot obtained with solution (A) corresponds in position, appearance and intensity with that obtained with solution (B). The test is not valid unless the chromatogram obtained with solution (C) shows 2 clearly separated spots.

C. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography using the conditions given under “Assay”, method B. The retention time of the principal peak in the chromatogram obtained with solution (1) corresponds to the retention time of the peak due to carbamazepine in the chromatogram obtained with solution (2).

D. Heat 0.1 g of the crystals with 2 mL of nitric acid (~1000 g/L) TS in a water-bath for 3 minutes; an orange-red colour is produced.

Impurity D. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography using the conditions given below under “Assay”, method B.

Prepare the following solutions. For solution (1) weigh and powder 20 tablets. Transfer a quantity of the powdered tablets containing about 0.15 g of carbamazepine into a 100 mL volumetric flask, shake with 50 mL of methanol R for about 15 minutes, dilute to volume with water R and filter. For solution (2) dilute 1 volume of solution (1) to 500 volumes with equal volumes of methanol R and water R. For solution (3) use a solution containing 10 µg of carbamazepine RS and 10 µg of carbamazepine impurity A RS per mL of a mixture of equal volumes of methanol R and water R.

Inject 20 μL of solution (3). The test is not valid unless the resolution between carbamazepine and carbamazepine impurity A is not less than 1.7.

Inject alternately 20 μL each of solution (1) and solution (2). Record the chromatograms for four times the retention time of carbamazepine. In the chromatogram obtained with solution (1) the following impurity, if present, is eluted at the following relative retention with reference to carbamazepine (retention time about 9 minutes): impurity D about 2.1.

In the chromatogram obtained with solution (1):

  • the area of any peak corresponding to impurity D, when multiplied by a correction factor of 0.4, is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (0.2%).

Dissolution. Carry out the test as described under 5.5 Dissolution test for solid oral dosage forms using as the dissolution medium 900 mL of a 1% solution of sodium dodecyl sulfate R in water and rotating the paddle at 75 revolutions per minute. At 60 minutes withdraw a sample of about 10 mL of the medium through an in-line filter. Allow the filtered sample to cool to room temperature. Measure the absorbance (1.6) of a 1 cm layer of the filtered sample, suitably diluted with dissolution medium if necessary, at the maximum at about 288 nm.

For each of the tablets tested calculate the amount of carbamazepine (C15H12N2O) in the medium using the absorptivity value of 49.0 ( = 490). Evaluate the results as described under 5.5 Dissolution test for solid oral dosage forms, Acceptance criteria.

The amount of carbamazepine in solution for each tablet is not less than 75% (Q) of the amount declared on the label.

Assay

  • Either method A or B may be applied.

A. Weigh and powder 20 tablets. To an accurately weighed quantity of the powder, containing about 0.06 g of carbamazepine, add 25 mL of ethanol (~750 g/L) TS and boil for a few minutes. Stir the hot mixture in a closed flask for 10 minutes and filter. Wash the flask with ethanol (~750 g/L) TS, filter and dilute the cooled filtrate with sufficient ethanol (~750 g/L) TS to produce 100.0 mL. Dilute 5.0 mL to 250.0 mL with the same solvent.

Measure the absorbance of a 1 cm layer of the solution at the maximum at about 285 nm against a solvent cell containing ethanol (~750 g/L) TS. Calculate the content of C15H12N2O using the absorptivity value of 49.0 ( = 490).

B. Carry out the test as described under 1.14.1 Chromatography, High-performance liquid chromatography using a stainless steel column (25 cm x 4.6 mm) packed with particles of silica gel, the surface of which has been modified with chemically-bonded cyanopropyl groups (10 μm). As the mobile phase use a mixture of 30 volumes of tetrahydrofuran R, 120 volumes of methanol R, 850 volumes of water R, 0.2 volume of anhydrous formic acid R and 0.5 volume of triethylamine R.

Operate with a flow rate of 2.0 mL per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of about 230 nm.

Prepare the following solutions. For solution (1) weigh and powder 20 tablets. Transfer a quantity of the powder equivalent to about 0.1 g of carbamazepine to a 100 mL volumetric flask, add 50 mL of methanol R and sonicate for about 15 minutes. Allow to cool to room temperature, make up to volume with water R and filter the solution. Dilute 10.0 mL of the filtrate to 50.0 mL with a mixture of equal volumes of methanol R and water R. For solution (2) use carbamazepine RS to obtain a solution containing 0.2 mg per mL of equal volumes of methanol R and water R.

Inject alternately 20 µL each of solution (1) and (2). The assay is not valid unless the column efficiency is at least 5000, determined for the peak due to carbamazepine in the chromatogram obtained with solution (2).

Measure the areas of the peaks corresponding to carbamazepine and calculate the content of carbamazepine (C15H12N2O) in the tablets using the declared content of C15H12N2O in carbamazepine RS.

Impurities. The impurity limited by the requirements of this monograph is impurity D listed in the monograph for carbamazepine.

to previous sectionto next section